Yale registers Phase 2 trial of Tonix's TNX-1900 for pituitary surgery pain
A new Yale-sponsored, Tonix-collaborated study of intranasal oxytocin will test its effect on post-surgical pain and neural function in pituitary patients.
A single new trial record for Tonix Pharmaceuticals was posted this week, listed as not yet recruiting.
- Yale University registered a Phase 2 trial (NCT07730294) of intranasal oxytocin formulation TNX-1900 in patients undergoing pituitary surgery, with Tonix Pharmaceuticals, Inc. listed as a collaborator. The study is a randomized, double-blind, placebo-controlled design to evaluate the efficacy of an intranasal oxytocin formulation, TNX-1900, on pain management, neural functioning, and socio-emotional health in patients undergoing pituitary surgery.1 The record lists an enrollment of 75 participants (estimated)1 and status not yet recruiting, with an estimated start of 2026-081. Primary outcomes include change in post-operative pain measured by the Numeric Pain Rating Scale (NPRS)1.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.